Brainstorm Cell Therapeutics Inc. Stock Forecast
Brainstorm Cell Therapeutics Inc. stock price ended on $1.55 on Friday after losing 2.21%
(Updated on Mar 24, 2023)
The Brainstorm Cell Therapeutics Inc. stock price fell by -2.21% on the last day (Friday, 24th Mar 2023) from $1.59 to $1.55. During the last trading day the stock fluctuated 5.96% from a day low at $1.51 to a day high of $1.60. The price has been going up and down for this period, and there has been a -4.32% loss for the last 2 weeks. Volume has increased on the last day by 331 shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 81 thousand shares were bought and sold for approximately $126.00 thousand.
Build a recession-proof portfolio with your existing stocks. Register to free live event. Ad
Given the current short-term trend, the stock is expected to rise 12.58% during the next 3 months and, with a 90% probability hold a price between $1.74 and $3.48 at the end of this 3-month period.
BCLI Signals & Forecast
There are few to no technical positive signals at the moment. The Brainstorm Cell Therapeutics Inc. stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $1.58 and $2.08. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Friday, February 10, 2023, and so far it has fallen -46.92%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Brainstorm Cell Therapeutics Inc. gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".
Support, Risk & Stop-loss for Brainstorm Cell Therapeutics Inc. stock
Brainstorm Cell Therapeutics Inc. finds support from accumulated volume at $1.54 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.0900 between high and low, or 5.96%. For the last week, the stock has had daily average volatility of 6.46%.
Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.
Trading Expectations (BCLI) For The Upcoming Trading Day Of Monday 27th
For the upcoming trading day on Monday, 27th we expect Brainstorm Cell Therapeutics Inc. to open at $1.55, and during the day (based on 14 day Average True Range), to move between $1.37 and $1.73, which gives a possible trading interval of +/-$0.176 (+/-11.34%) up or down from last closing price. If Brainstorm Cell Therapeutics Inc. takes out the full calculated possible swing range there will be an estimated 22.69% move between the lowest and the highest trading price during the day.
Since the stock is closer to the resistance from accumulated volume at $1.56 (0.65%) than the support at $1.54 (0.65%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.
Is Brainstorm Cell Therapeutics Inc. stock A Buy?
The Brainstorm Cell Therapeutics Inc. stock holds several negative signals and despite the positive trend, we believe Brainstorm Cell Therapeutics Inc. will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.
Current score: -4.767 Open Broker Account
Sell Candidate UnchangedPredicted Opening Price for Brainstorm Cell Therapeutics Inc. of Monday, March 27, 2023
The predicted opening price is based on yesterday's movements between high, low, and closing price.
| Fair opening price March 27, 2023 | Current price |
|---|---|
| $1.55 | $1.55 (Undervalued) |
Remember To Visit Our YouTube Channel
Trading levels for BCLI
Fibonacci Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 1.64 | 6.02 % | |
| R2 | 1.61 | 3.80 % | ||
| R1 | 1.59 | 2.43 % | ||
| Current price: | 1.55 | |||
| Support | S1 | 1.52 | -2.00 % | |
| S2 | 1.50 | -3.37 % | ||
| S3 | 1.46 | -5.59 % |
Accumulated Volume Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 1.70 | 9.68 % | |
| R2 | 1.62 | 4.52 % | ||
| R1 | 1.56 | 0.645 % | ||
| Current price | 1.55 | |||
| Support | S1 | 1.54 | -0.645% | |
| S2 | 1.52 | -1.94% | ||
| S3 | 1.47 | -5.16% |
FAQ
Click here for our free guide on how to buy Brainstorm Cell Therapeutics Inc. Stock.
About Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative ... BCLI Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
